HEPATOCELLULAR CARCINOMA AND SMOKING ARE INDEPENDENT RISK FACTORS FOR DEVELOPMENT OF DE-NOVO EXTRAHEPATIC TUMORS IN LIVER TRANSPLANT RECIPIENTSDIGESTIVE AND LIVER DISEASEIF3.82019-03-010PREAI
EFFICACY AND SAFETY OF PERCUTANEOUS LASER ABLATION THERAPY FOR TREATMENT OF LARGE HCCDIGESTIVE AND LIVER DISEASEIF3.82016-02-011PREAI
EFFICACY AND SAFETY OF PERCUTANEOUS LASER ABLATION THERAPY FOR TREATMENT OF LARGE HEPATOCELLULAR CARCINOMAJOURNAL OF HEPATOLOGYIF332016-01-010PREAI
Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinomaFUTURE ONCOLOGYIF2.62015-03-1128PREAI
Radiofrequency ablation versus laser ablation for the treatment of small hepatocellular carcinoma in cirrhosis: A randomized trial射频消融与激光消融治疗肝硬化小肝癌的随机对照研究JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGYIF3.42015-02-2368PREAI
Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practiceDIGESTIVE AND LIVER DISEASEIF3.82012-09-0131PREAI
SAFETY AND EFFECTIVENESS OF TREATMENT WITH SORAFENIB IN ELDERLY CIRRHOTIC PATIENTS AFFECTED BY ADVANCED HEPATOCELLULAR CARCINOMADIGESTIVE AND LIVER DISEASEIF3.82011-03-010PREAI
RADIOFREQUENCY ABLATION VERSUS LASER ABLATION FOR THE TREATMENT OF SMALL HEPATOCELLULAR CARCINOMA: A RANDOMIZED CONTROLLED TRIALDIGESTIVE AND LIVER DISEASEIF3.82011-03-011PREAI
SAFETY AND EFFECTIVENESS OF TREATMENT WITH SORAFENIB IN ELDERLY CIRRHOTIC PATIENTS AFFECTED BY ADVANCED HEPATOCELLULAR CARCINOMAJOURNAL OF HEPATOLOGYIF332011-03-010OAAI
PREDICTIVE FACTORS FOR TUMOR CONTROL AMONG HEPATOCELLULAR CARCINOMA PATIENTS TREATED WITH SORAFENIBDIGESTIVE AND LIVER DISEASEIF3.82011-03-010PREAI
PEG-INTERFERON PLUS RIBAVIRIN TREATMENT DOES NOT IMPROVE RECURRENCE AFTER RESECTION OR ABLATION OF HEPATOCELLULAR CARCINOMA IN HCV CIRRHOTIC PATIENTS: A CASE-CONTROL STUDYJOURNAL OF HEPATOLOGYIF332011-03-010PREAI
FACTORS PREDICTIVE FOR TUMOR CONTROL AMONG HEPATOCELLULAR CARCINOMA PATIENTS TREATED WITH SORAFENIBJOURNAL OF HEPATOLOGYIF332011-03-010PREAI
SORAFENIB FOR THE TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA: EFFECTIVENESS AND IMPACT OF ADVERSE EFFECTS IN DAILY CLINICAL PRACTICEDIGESTIVE AND LIVER DISEASEIF3.82011-03-010PREAI
Peginterferon Alfa-2a Plus Ribavirin Is More Effective Than Peginterferon Alfa-2b Plus Ribavirin for Treating Chronic Hepatitis C Virus InfectionGASTROENTEROLOGYIF25.12010-01-01157OA
DEVELOPMENT AND VALIDATION OF THE NAPOLI PROGNOSTIC INDEX (NAPI): A NEW RISK SCORE FOR PREDICTING DEATH IN CIRRHOTIC PATIENTS WITH TREATABLE HEPATOCELLULAR CARCINOMA (HCC)JOURNAL OF HEPATOLOGYIF332009-04-010OAAI
Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantationJOURNAL OF HEPATOLOGYIF332007-03-01166PREAI
Impact of alcohol consumption, cigarette smoking and diabetes on the occurrence of hepatocellular carcinoma in patients with HCV-related cirrhosis and a known length of viral infectionJOURNAL OF HEPATOLOGYIF332004-01-010PREAI
Prospective analysis of risk factors for survival and intrahepatic recurrence of hepatocellular carcinoma (HCC) following ethanol injectionJOURNAL OF HEPATOLOGYIF332003-04-010PREAI
Endoscopic management of foreign bodies in the upper gastrointestinal tract: Report on a series of 414 adult patientsENDOSCOPYIF12.82001-08-01154PREAI